Study of Focal Airway Disease in Asthma Using Image Guided Bronchoscopy
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Difference in eosinophil percentage in broncheoalveolar biospecimens between asthmatic and non-asthmatic airways
研究概览
简要总结
This is a single center study of 60 subjects including those with asthma and mucus plugging, those with asthma and without mucus plugging, and healthy controls. Screening data will be reviewed to determine participant eligibility. Participants who meet all inclusion criteria will participate in image-guided bronchoscopy ("virtual navigation bronchoscopy" [VNB]) to sample airway biospecimens in mucus plugged and control airways.
详细描述
This is a single center study of 60 subjects. The investigators will enroll 30 subjects with asthma who demonstrate mucus plugging on a screening CT lung scan, 15 subjects with asthma without mucus plugging, and 15 healthy controls. The healthy controls and subjects with asthma but without mucus plugging with also undergo CT scans to confirm that their lungs aren't obstructed by mucus.
Screening data will be reviewed to determine participant eligibility. Participants who meet all inclusion criteria will participate in image-guided bronchoscopy ("virtual navigation bronchoscopy" [VNB]) to sample airway biospecimens in mucus plugged and control airways. Subjects will participate in up to 5 study visits at the Airway Clinical Research Center.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Group 1: Healthy Controls
- •Inclusion Criteria:
- •Male or female between the ages of 18 and 70 years at Visit 1 and at least 50% whose age is > 40 years (to ensure age balance among groups and anticipating that group 3 subjects will be older).
- •Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
- •Able to perform reproducible spirometry according to ATS criteria.
排除标准
- •Upper respiratory tract infection (URI) within the previous 6 weeks.
- •History of lung disease.
- •Smoking of tobacco or other recreational inhalants in last month and/or >10 pack-year smoking history.
- •Currently pregnant.
- •History of allergic rhinitis.
- •Laboratory evidence of atopy (blood eosinophils > 0.4 cells/dL, IgE > 165 IU/mL)
- •History of unstable cardiovascular disease.
- •BMI > 45
- •Currently taking anticoagulants.
- •Group 2: Asthmatic Subjects without Mucus Plugs
- •Inclusion Criteria:
- •Male or female between the ages of 18 and 70 years at Visit 1 and at least 50% whose age is > 40 years (to ensure age balance among groups and anticipating that group 3 subjects will be older).
- •Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
- •Able to perform reproducible spirometry according to ATS criteria.
- •Physiological evidence of airflow obstruction (FEV1 bronchodilator reversibility of ≥ 12% or hyperreactivity to methacholine reflected by a methacholine PC20 ≤ 16 mg/mL). Historical methacholine data from previous studies conducted in the past 5 years at the UCSF ACRC will be allowed.
- •Clinical history of asthma per patient report or medical record.
- •Asthma requiring treatment with inhaled corticosteroids (ICS) for 3 months or greater.
- •Exclusion Criteria:
- •Asthma exacerbation or URI within the previous 6 weeks.
- •Currently pregnant.
- •Smoking of tobacco or other recreational inhalants in last month and/or >10 pack-year smoking history.
- •Other chronic pulmonary disorders, including cystic fibrosis and chronic obstructive pulmonary disease.
- •History of unstable cardiovascular disease.
- •Currently taking anticoagulants.
- •Group 3: Asthmatic Subjects with Mucus Plugs
- •Male or female between the ages of 18 and 70 years at Visit
- •Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
- •Able to perform reproducible spirometry according to ATS criteria.
- •Physiological evidence of airflow obstruction (FEV1 bronchodilator reversibility of ≥ 12% or hyperreactivity to methacholine reflected by a methacholine PC20 ≤ 16 mg/mL). Historical methacholine data from previous studies conducted in the past 5 years at the UCSF ACRC will be allowed.
- •Clinical history of asthma per patient report or medical record.
- •Asthma requiring treatment with inhaled corticosteroids (ICS) for 3 months or greater.
- •A MDCT lung scan indicating a mucus plug accessible by bronchoscopy in at least one airway.
- •Exclusion Criteria:
- •Asthma exacerbation or URI within the previous 6 weeks.
- •Currently pregnant.
- •Smoking of tobacco or other recreational inhalants in last month and/or >10 pack-year smoking history.
- •Other chronic pulmonary disorders, including cystic fibrosis and chronic obstructive pulmonary disease.
- •History of unstable cardiovascular disease.
- •Currently taking anticoagulants.
- •Mucus plugs inaccessible by bronchoscope.
研究组 & 干预措施
Healthy Controls
Participants with no history of asthma or other lung diseases.
干预措施: Multidetector Computed Tomography (MDCT) Scan (Radiation)
Healthy Controls
Participants with no history of asthma or other lung diseases.
干预措施: Virtual Navigation Bronchoscopy (VNB) (Procedure)
Asthmatics without mucus plugs
Participants with asthma and no evidence of mucus plugging.
干预措施: Multidetector Computed Tomography (MDCT) Scan (Radiation)
Asthmatics without mucus plugs
Participants with asthma and no evidence of mucus plugging.
干预措施: Virtual Navigation Bronchoscopy (VNB) (Procedure)
Asthmatics with mucus plugs
Participants with asthma and evidence by MDCT lung scan showing mucus plugging.
干预措施: Multidetector Computed Tomography (MDCT) Scan (Radiation)
Asthmatics with mucus plugs
Participants with asthma and evidence by MDCT lung scan showing mucus plugging.
干预措施: Virtual Navigation Bronchoscopy (VNB) (Procedure)
结局指标
主要结局
Difference in eosinophil percentage in broncheoalveolar biospecimens between asthmatic and non-asthmatic airways
时间窗: 6 months
The investigators will examine differences in type-2 inflammatory markers in bronchoalveolar biospecimens. Eosinophils are an indicator of type 2 inflammation in bronchial lavage samples. Indicators of airway inflammation will be compared with healthy control biospecimens and those of non-mucus plugged asthmatics.
Difference in gene expression of genes that mark IL-13 activation between asthmatic and non-asthmatic airways
时间窗: 6 months
Genes such as periostin, CLCA1, and Serpin B2 will be analyzed for expression in epithelial cell brushings.
次要结局
未报告次要终点